Form 4: Centene Director Adjusts Stock Holdings

Centene Director Christopher J. Coughlin reported changes in his beneficial ownership of common stock and derivative securities, including a grant of 729 shares and a restructuring of shares held in a grantor retained annuity trust.

Summary

• Director Christopher J. Coughlin reported changes in his beneficial ownership of Centene Corp (CNC) securities.
• Acquired 729 shares of common stock on December 31, 2025, at a price of $0, likely as a grant or award.
• Restructured 30,054 shares of common stock held in a grantor retained annuity trust (GRAT). On November 13, 2025, these shares were moved from an existing GRAT to an individual account, and then on November 19, 2025, they were contributed to a new GRAT for the benefit of himself and his adult children.
• Direct beneficial ownership of common stock is 13,016.926 shares, which includes 3,579 restricted stock units subject to vesting requirements.
• Indirect beneficial ownership of common stock is 30,054 shares held by a Grantor Retained Annuity Trust.
• Directly owns 10,000 common stock options with an exercise price of $80.57, exercisable from February 7, 2025, and expiring on February 7, 2032.

Sentiment

Score: 6

Explanation: The filing reports a director's acquisition of 729 shares, which is a minor positive. The restructuring of GRAT shares is a neutral event in terms of net beneficial ownership. Overall, it's a routine insider transaction with a slight positive tilt due to the acquisition.

Positives

• Acquisition of 729 shares of common stock by a director, potentially indicating confidence in the company's future prospects.

Risks

• 3,579 shares of restricted stock units included in direct beneficial ownership are subject to vesting requirements, meaning full ownership is contingent on meeting specific conditions.

Future Outlook

The filing does not provide a future outlook for the company, focusing solely on insider transaction details.

Industry Context

This Form 4 filing details routine insider transactions for a director of Centene Corp, a major player in the managed healthcare industry. Such filings are standard regulatory disclosures and typically do not reflect broader industry trends unless they indicate a significant shift in insider sentiment or a large-scale divestment/acquisition program across multiple insiders.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all publicly traded companies.
• The transactions reported, including stock grants and the restructuring of shares within a grantor retained annuity trust, are common practices for executive compensation and estate planning among directors and officers in the healthcare sector and other industries.
• There are no specific comparable companies or projects mentioned in this filing to assess against.

Related Party Transactions

• Restructuring of 30,054 common shares within a grantor retained annuity trust for the benefit of the director and his adult children, where the director is the sole trustee.

Stakeholder Impact

• Shareholders: The acquisition of 729 shares by a director could be seen as a minor positive signal of confidence in the company's value. The GRAT restructuring has no direct impact on the company's outstanding shares or market valuation.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including a small acquisition of shares and a restructuring of shares within a grantor retained annuity trust by a director. While the acquisition of shares by an insider can be a minor positive signal, the overall impact of these transactions on the company's fundamentals or strategic direction is negligible. There is no new information presented that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Centene Corp, CNC, Form 4, Insider Trading, Director Stock, Stock Options, Restricted Stock Units, Grantor Retained Annuity Trust, Beneficial Ownership